Director · REGENERON PHARMACEUTICALS, INC. · Common Stock
Side
A
Value
—
Shares
155
Price
—
Executed
Jan 2, 2026
Disclosed
Jan 6, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 6, 2026 disclosed
REGN · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 34.6% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Guarini Kathryn filed this Form 4 reporting a grant or award of REGN on Jan 2, 2026. It became public on Jan 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Guarini Kathryncik:0001992352
Issuer
REGENERON PHARMACEUTICALS, INC.cik:0000872589
Revision history · 0
No field has changed since this record was first ingested.
